title: Effects of the renin angiotensin system on vasculogenesis-related progenitor cells.
abstract: The current concept is that there are both cells that integrate into the vasculature, true endothelial progenitor cells (EPC), and cells with hematopoietic markers that support neovascularisation. As identification of the EPC is controversial and studies refer cells that might fall into either pools, we will use the term, vasculogenesis-related progenitor cells (VRPC), for this review. VRPC are considered to be an important target for the treatment of cardiovascular diseases (CVD). Angiotensin II is known to be an important player in neovascularisation and the modulation of renin angiotensin system (RAS) is one of the major pharmacotherapeutic strategies for the treatment of CVD. We will review the effects of different components of the RAS on such VRPC under physiological conditions and in CVD. The reviewed research strongly supports a critical role of the RAS in vasculogenesis and vascular regeneration. Therefore, pharmacological intervention on the components of the RAS does not only target directly end-organ remodelling and blood pressure but also influence tissue healing and/or regeneration by influencing specific progenitor cells. Thus, the interrogation of RAS effects on VRPC will be important in the optimisation of RAS intervention or regenerative therapy.
authors.affiliation: Department of Internal Medicine, Section of Pharmacology, Vascular and Metabolic Disease, Erasmus Medical Centre, Rotterdam, The Netherlands.
authors.forename: Anton J M
authors.initials: AJ
authors.lastname: Roks
authors.forename: Kathy
authors.initials: K
authors.lastname: Rodgers
authors.forename: Thomas
authors.initials: T
authors.lastname: Walther
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000809:Angiotensins / Q000502:physiology; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000166:cytology*; D006410:Hematopoiesis; D006801:Humans; D018919:Neovascularization, Physiologic / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000502:physiology*; D013234:Stem Cells / Q000187:drug effects / Q000502:physiology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D017382:Reactive Oxygen Species